EJHaem · 2026
Targeting CD162 for Life-Threatening Cutaneous Chronic Graft-Versus-Host Disease: A Case Report.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lieberman Alicia, McCauley Ross, Ross Maureen, McCarthy Philip, Cho Iming, Reed Simona, Lin Shih-Yao, Chou Judy, Holtan Shernan G
Аннотация
UNLABELLED: Steroid-refractory chronic cutaneous graft-versus-host disease (GVHD) causes substantial morbidity, prolonged hospitalization, and non-relapse mortality after allogeneic hematopoietic cell transplantation. We report a young adult with multisystem chronic GVHD and recurrent life-threatening inflammatory skin flares refractory to multiple standard therapies, with cumulative inpatient care exceeding 1 year. Under an institutional review board-approved compassionate-use protocol, he received a non-cytotoxic monoclonal antibody targeting CD162 (P-selectin glycoprotein ligand-1). Treatment was associated with durable resolution of active cutaneous GVHD, corticosteroid reduction, improved mobility, and meaningful recovery in daily function and quality of life.
TRIAL REGISTRATION: The author has confirmed clinical trial registration is not needed for this submission.
TRIAL REGISTRATION: The author has confirmed clinical trial registration is not needed for this submission.